Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation (Q28196075)

From Wikidata

Jump to navigation Jump to search

scientific article (publication date: 2003)

Language	Label	Description	Also known as
English	Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation	scientific article (publication date: 2003)

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12749745%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

Europe PubMed Central

Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12749745%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

revascularization

1 reference

based on heuristic

inferred from title

arteriosclerotic heart disease

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12749745%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

author name string

Jane K McGavin

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12749745%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Karen L Goa

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12749745%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

language of work or name

0 references

publication date

1 January 2003

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12749745%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12749745%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

63

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12749745%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12749745%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1121-1163

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12749745%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200363110-00014

21 January 2018

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200363110-00014

21 January 2018

Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200363110-00014

21 January 2018

Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200363110-00014

21 January 2018

High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trends

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-efficacy in interventional cardiology; results from the EPISTENT study. Evaluation of Platelet IIb/IIIa Inhibitor For Stenting Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of Abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantification by flow cytometry of the efficacy of and interindividual variation of platelet inhibition induced by treatment with tirofiban and abciximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects on thrombin generation of the platelet glycoprotein IIb/IIIa inhibitors abciximab versus tirofiban during coronary intervention

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions. International Cardiology Forum

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of Markers of Platelet Activation and the Interpatient Variation in Response to Abciximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Readministration of abciximab in percutaneous coronary intervention

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE)

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tirofiban. A review of its use in acute coronary syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Coronary Stenting plus Platelet Glycoprotein IIb/IIIa Blockade Compared with Tissue Plasminogen Activator in Acute Myocardial Infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abciximab readministration: results of the ReoPro Readministration Registry

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Costs and effects of combining stenting and abciximab (ReoPro) in daily practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fortnightly review: Intracoronary stents

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome wit

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abciximab Inhibits the Migration and Invasion Potential of Human Coronary Artery Smooth Muscle Cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abciximab provides cost-effective survival advantage in high-volume interventional practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ex vivo--in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination therapy for acute myocardial infarction: fibrinolytic therapy and glycoprotein IIb/IIIa inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of abciximab and coronary stenting on outcomes and costs of percutaneous coronary interventions in a community hospital

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of vascular smooth muscle cell adhesion and migration by c7E3 Fab (abciximab): a possible mechanism for influencing restenosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of abciximab versus tirofiban on hospital length of stay for PCI patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo demonstration of an antithrombin effect of abciximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of abciximab versus eptifibatide on length of hospital stay for PCI patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, alphaMbeta2).

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abciximab. An updated review of its use in ischaemic heart disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute coronary syndrome without ST elevation: implementation of new guidelines

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Platelet CD62 expression and PDGFAB secretion in patients undergoing PTCA and treatment with abciximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abciximab. A pharmacoeconomic review of its use in percutaneous coronary revascularisation

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization: Pooled analysis from EPIC, EPILOG, and EPISTENT

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimal treatment of acute coronary syndromes--an evolving strategy

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Facilitated PCI: rationale and design of the FINESSE trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of abciximab, ticlopidine, and combined Abciximab/Ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Defining the role of abciximab for acute coronary syndromes: lessons from CADILLAC, ADMIRAL, GUSTO IV, GUSTO V, and TARGET.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antithrombotic effects of Abciximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlo

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The benefit of abciximab in percutaneous coronary revascularization is not device-specific

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[An economic assessment of the use of abciximab as a coronary angioplasty preparation in the Italian health-care context]

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness and safety of abciximab after failed thrombolytic therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abciximab reduces mortality in diabetics following percutaneous coronary intervention.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of abciximab readministration in coronary intervention.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimizing Percutaneous Coronary Revascularization in Diabetic Women: Analysis from the EPISTENT Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST-segment elevation acute coronary syndromes. Estimating the economic implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the M

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A new type of pseudothrombocytopenia: EDTA-mediated agglutination of platelets bearing Fab fragments of a chimaeric antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/12749745

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28196075&oldid=2177499860"